Company Profiles

driven by the PitchBook Platform

PharmaNeuroBoost

2006 FOUNDED
OOB STATUS
Liquidation LATEST DEAL TYPE
$30.7M TOTAL AMOUNT RAISED
Description

Operator of bio pharmaceutical business intended to exploit the PNB01 and PNB02 opportunity for psychiatric disorders. The company's bio pharmaceutical business develops two anti-depression drugs PNB01 and PNB02, enabling treatment of depressive disorder and schizophrenia.

Ownership Status
Out of Business
Financing Status
Formerly PE-Backed
Primary Industry
Pharmaceuticals
Primary Office
Alkerstraat 30 A
3570 Alken
Belgium
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore PharmaNeuroBoost’s full profile, request a free trial.

PharmaNeuroBoost Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Bankruptcy: Liquidation 18-Mar-2013 $30.7M Completed Bankruptcy: Liquidation
4. PE Growth/Expansion 14-Nov-2013 000.00 Completed Generating Revenue
3. PE Growth/Expansion 18-Jan-2011 0000 000.00 Completed Generating Revenue
2. PE Growth/Expansion 01-Oct-2008 $8.68M $10.7M Completed Startup
1. Early Stage VC 31-Dec-2006 $1.98M $1.98M Completed Startup
To view this company’s complete deal history including valuation and funding request access »

PharmaNeuroBoost Executive Team (1)

Name Title Board
Seat
Contact
Info
Erik Buntix MD Founder, Chief Executive Officer & Chief Scientific Officer